GeneDx Holdings Corp. Investors Encouraged to Join Class Action Against Company over Stock Decline

Investment Alert: Join the GeneDx Class Action

In a significant development for investors of GeneDx Holdings Corp. (NASDAQ: WGS), the law firm Robbins Geller Rudman & Dowd LLP has announced that individuals who purchased stock in the company between April 16, 2025, and May 4, 2026, are encouraged to step forward as lead plaintiffs in a potential class action lawsuit. This opportunity arises for those who suffered substantial losses during this period, which is crucial for asserting their rights under securities law.

Legal Background of the Case

The lawsuit, referred to as Basma v. GeneDx Holdings Corp. and numbered 26-cv-00880 in the District of Connecticut, alleges that GeneDx, alongside its top executives, violated provisions of the Securities Exchange Act of 1934. Investors are claiming that the company made misleading statements about its financial health and future prospects, particularly following its announcement of acquiring Fabric Genomics, a firm specializing in AI-driven genomic interpretation.

Timeline of Events

On April 16, 2025, GeneDx made headlines with its strategic acquisition of Fabric Genomics. Investors were optimistic initially; however, the narrative took a downturn when, on May 4, 2026, the company released its first-quarter results for 2026. These results revealed a concerning drop in adjusted gross margins from 74% to 69%, as well as a downward revision of projected earnings from between $540 million to $555 million down to a lower range of $475 million to $490 million. Furthermore, the announcement included a hefty impairment loss of $31.3 million linked directly to Fabric Genomics’ performance.

Upon this news, GeneDx's stock price plummeted by over 49%, prompting many investors to reconsider their positions and seek legal recourse.

The Role of a Lead Plaintiff

Under the Private Securities Litigation Reform Act of 1995, any investor who purchased GeneDx common stock during the specified class period can apply to serve as a lead plaintiff. The lead plaintiff is generally considered the individual with the most significant financial interest in the lawsuit and is crucial in guiding the case against GeneDx. Furthermore, being a lead plaintiff allows the individual to select a law firm of their preference to represent their interests.

It's important to note that participating as a lead plaintiff is not a prerequisite for recovering potential damages. All investors who suffered losses may be entitled to a portion of any recovery, regardless of whether they take on the lead plaintiff role.

About Robbins Geller Rudman & Dowd LLP

Robbins Geller Rudman & Dowd LLP is among the most prestigious law firms globally, focusing on advocating for investors involved in securities fraud cases. In 2025 alone, they secured more than $916 million for their clients and have consistently ranked as a top performer in the domain of securities class action. The firm has a well-established reputation, having achieved some of the largest recoveries in the industry's history.

For those interested in learning more about this case or considering participation, you can contact attorneys Ken Dolitsky or Michael Albert at Robbins Geller by calling 800/851-7783 or via email at [email protected]. More information about their services can also be found on their website.

Conclusion

The unfolding situation with GeneDx Holdings Corp. is a vital reminder for investors to remain vigilant and informed regarding the financial health of the companies they choose to invest in. This class action lawsuit serves as an opportunity for those affected to hold the company accountable and potentially recover their losses. Investors must act before the deadline of August 3, 2026, to ensure they have the chance to step up as lead plaintiffs or at least support the wider investor campaign against the company's misleading practices.